Texas Pacific Land Trust

Texas Pacific Land and Taiwan Semiconductor Manufacturing were top contributors for both the quarter and the year, showcasing strong earnings growth and strategic market positioning. Despite Texas Pacific Land's strong performance, we sold our positions due to overvaluation driven by index additions, with plans to re-invest post-market correction. Edwards Lifesciences' EARLY TAVR trial results highlight significant potential for expanding aortic stenosis treatment, positioning the company for double-digit earnings growth in the coming years.» Mehr auf seekingalpha.com

The stock of Texas Pacific Land is experiencing aggressive upward momentum, delivering strong gains of +260% over the past two years. Its rally has seen minimal pullbacks, indicating a solid shareholder base. At current levels, the stock is trading 35% below its trend peak, presenting a re-entry opportunity.» Mehr auf seekingalpha.com

TPL achieved a record in the third quarter of 2024, with oil and gas royalty production reaching 28,300 barrels of oil equivalent per day.» Mehr auf zacks.com